Ovulation induction and intrauterine insemination in infertile women with polycystic ovary syndrome: A comparison of drugs

Huang, Shuo; Du, Xiaoguo; Wang, Rui; Li, Rong; Wang, Haiyan; Luo, Li; O’Leary, Seán; Qiao, Jie; Mol, Ben Willem J.

doi:10.1016/j.ejogrb.2018.08.002

Cited by 21 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study, mono-follicular development rates and singleton pregnancy rates were higher in PCOS patients with LTZ than CC. 24 However, in an extensive series of meta-analysis, there was no significant difference between the multiple pregnancy rates of LTZ and CC. 17 In this study, the mean number of follicles ≥14 mm was similar, and there were no multiple gestations in both groups.…”

Section: Discussionmentioning

confidence: 96%

Letrozole is superior to clomiphene citrate in ovulation induction in patients with polycystic ovary syndrome

Şakar

Oğlak

2020

Pak J Med Sci

View full text Add to dashboard Cite

Objective: This study was aimed to compare the clinical outcomes of ovulation induction (OI) by timed intercourse with letrozole (LTZ) and clomiphene citrate (CC). Methods: Three hundred and twenty-three patients with polycystic ovary syndrome (PCOS) who underwent OI with LTZ or CC between February 2017 and November 2018 were included in this retrospective study. The patients were divided into two groups as the CC group (n=148) and the LTZ group (n=175). Endometrial thickness, follicular development, ovulation, clinical pregnancy, abortion, and live birth rates of the groups were analyzed. Results: The mean endometrium thickness of the CC group was 7.1±1.7 mm, and the LTZ group was 8.6±1.8 mm (p<0.001). The ovulation rate per cycle was higher in the LTZ group (93.1%) in comparison with the CC group (83.8%) (p=0.013). Clinical pregnancy rates were 52% in the LTZ group, and 41.2% in the CC group (p=0.047). LTZ with 44% of live birth rate was superior to CC with a 33% live birth rate (p=0.029). Conclusions: LTZ is an effective OI agent in PCOS patients. LTZ is superior to CC in terms of pregnancy rates and live birth rates. As a result, we recommend that LTZ should be the first-line treatment agent in patients with PCOS. doi: https://doi.org/10.12669/pjms.36.7.3345 How to cite this:Sakar MN, Oglak SC. Letrozole is superior to clomiphene citrate in ovulation induction in patients with polycystic ovary syndrome. Pak J Med Sci. 2020;36(7):1460-1465. doi: https://doi.org/10.12669/pjms.36.7.3345 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Discussionmentioning

confidence: 96%

Letrozole is superior to clomiphene citrate in ovulation induction in patients with polycystic ovary syndrome

Şakar

Oğlak

2020

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…On the contrary, several studies reported higher multi-follicular growth on the day of hCG in CC cycles compared to FSH cycles (Danhof et al, 2018;Peeraer et al, 2015). However, Huang et al (2018) reported that the percentages of mono-follicular development were 67% and 72.9% for the CC and FSH groups, respectively. In the present study, we found similar mono-follicular development rates; 75.1% and 75.5% in the CC and FSH treatment arms, respectively.…”

Section: Discussionmentioning

confidence: 93%

“…However, we failed to show a significant difference between rFSH and CC when adjusted for the number of follicles developed. In the literature, the CPR was generally higher in the FSH groups when the multi-follicular growth occurs, but the differences were not statistically significant (Berker et al, 2011;Huang et al, 2018). Zolton et al (2020) also justified the effect of gonadotrophins against the oral agents for unexplained infertility.…”

Section: Discussionmentioning

confidence: 99%

Clomiphene Citrate versus Recombinant FSH in intrauterine insemination cycles with mono- or bi-follicular development

Tokgöz¹,

Şükür²,

Özmen³

et al. 2021

JBRA

View full text Add to dashboard Cite

“…Thus, it would be prudent to determine the factors favoring pregnancy in ovulation induction cycles (6,7). The factors associated with the success of ovulation induction cycles have been identified as female age, type, and duration of infertility, the number of mature follicles recruited and endometrial thickness (8)(9)(10). Although results usually compromise with some of these factors, there is still a lack of consistency in terms of other factors such as sex hormones.…”

Section: Introductionmentioning

confidence: 99%

Success Rates of Clomiphene Citrate and Recombinant Gonadotropin Cycles: A Single-Center Experience

Gürlek

Batioğlu

Kanat-Pektaş

et al. 2020

Gynecol Obstet Reprod Med

View full text Add to dashboard Cite

Objective: This aim of this study is to assess the ovulation induction cycles based on clomiphene citrate and gonadotropin administration and specify the factors associated with successful outcomes. Study Design: This is a prospective study of 631 patients who underwent 917 ovulation induction cycles. While clomiphene citrate was used in 680 cycles (74.2%) and recombinant follicle-stimulating hormone was administered in 237 cycles (25.8%). Results: A total of 153 pregnancies were achieved in 917 ovulation induction cycles, indicating a clinical pregnancy rate of 16.7%. The ovulation induction cycles which ended up with clinical pregnancy had a significantly lower frequency of smoking (p=0.005), shorter infertility duration (p=0.001), higher basal luteinizing hormone (p=0.021) and lower basal progesterone (p=0.008) than unsuccessful cycles. The clomiphene citrate cycles which ended up with clinical pregnancy had a significantly lower frequency of smoking (p=0.011), shorter infertility duration (p=0.001) and lower basal progesterone (p=0.013) than the unsuccessful cycles. The recombinant follicle-stimulating hormone cycles which ended up with clinical pregnancy had a significantly higher basal luteinizing hormone (p=0.008) than the unsuccessful cycles. Basal luteinizing hormone and progesterone concentrations could significantly distinguish the patients who were able to conceive in ovulation induction cycles (p=0.021 and p=0.008, respectively).Conclusions: Smoking, longer duration of infertility, and elevated basal progesterone are poor prognostic factors for clinical pregnancy in clomiphene citrate and recombinant follicle-stimulating hormone cycles.

show abstract

Ovulation induction and intrauterine insemination in infertile women with polycystic ovary syndrome: A comparison of drugs

Cited by 21 publications

References 15 publications

Letrozole is superior to clomiphene citrate in ovulation induction in patients with polycystic ovary syndrome

Letrozole is superior to clomiphene citrate in ovulation induction in patients with polycystic ovary syndrome

Clomiphene Citrate versus Recombinant FSH in intrauterine insemination cycles with mono- or bi-follicular development

Success Rates of Clomiphene Citrate and Recombinant Gonadotropin Cycles: A Single-Center Experience

Contact Info

Product

Resources

About